It sounds like OpenAI has been having some exciting discussions with the bigwigs at the U.S. Food and Drug Administration (FDA). As per Wired, who brought us the news this Wednesday, they have been brainstorming on how AI can zip up the process of evaluating new medications.

At the heart of these discussions is a nifty little project codenamed cderGPT. It appears that the Center for Drug Evaluation (CDE) will use this AI-powered use. If you didn't already know, the CDE is the U.S.command center for keeping tabs on all over-the-counter and prescription drugs. Joining OpenAI and the FDA on this tech adventure has been Elon Musk’s team from DOGE as well.

The fact is, bringing a new drug from the lab to your local pharmacy can be a painfully slow journey of 10 years or more. And that's where OpenAI is aiming to make a difference, by applying AI to trim time off that long, winding road of drug development. Specifically, they want to speed up the final stretch, according to Wired. It's no secret that the tech world sees AI as a game-changer for the sluggish steps in drug development. However, the lingering question is how to rein in the unpredictable nature of AI models.